查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143567

單胺氧化酵素抑制劑市場：全球市場預測，2026-2032年

Monoamine Oxidase Inhibitors Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，單胺氧化酵素抑制劑市場規模將達到 25.7 億美元，複合年成長率為 7.31%。

主要市場統計數據
基準年 2025 15.7億美元
預計年份：2026年 16.5億美元
預測年份 2032 25.7億美元
複合年成長率 (%) 7.31%

單胺氧化酵素抑制劑在現代神經精神治療的應用

單胺氧化酵素抑制劑（MAOIs）是處方藥，主要用於治療某些類型的憂鬱症，某些劑型也可用於治療帕金森氏症。這些藥物透過抑制單胺類神經傳導物質（如血清素、正腎上腺素和多巴胺）的分解來發揮作用。儘管其臨床應用受到與食物和其他藥物相互作用、副作用風險以及其他治療方法可用性的限制，但當其他治療方法無效或出於特定臨床需求時，它們仍然發揮著重要作用。

安全管理和治療作用正在改變這些設備的使用方式。

治療方法正在發生變化，越來越重視藥物調整、飲食指導、藥物交互作用篩檢和專科醫生監督。臨床醫生必須區分不可逆抑制和可逆抑制，考慮藥物清除期，並管理與高血壓反應和血清素毒性相關的風險。雖然經皮和選擇性製劑可能緩解一些實際障礙，但患者教育和協調護理的重要性日益凸顯，同時，個人化治療方案的選擇和更全面的追蹤也變得尤為重要。

人工智慧將有助於做出更安全、更個人化的決策。

人工智慧 (AI) 可透過識別複雜用藥清單中潛在的藥物交互作用、預警禁忌組合以及支援臨床決策流程，為單胺氧化酶抑制劑 (MAOI) 的治療做出貢獻。它還可以透過檢測不利事件報告中的模式來協助藥物安全監測，幫助研究人員識別與治療反應或不耐受相關的患者特徵。這些應用需要檢驗的臨床證據、透明的推理過程、隱私保護以及臨床醫生的監督。人工智慧應輔助而非取代處方決策。

地區差異反映了法規、准入條件和專家的可近性。

在北美和歐洲，既定的處方指南、專科醫生服務以及詳細的互動管理要求影響人工智慧的應用。在亞太地區，澳洲、日本和韓國等國家擁有先進的神經精神科醫療服務，但全部區域在醫療資源取得和臨床基礎設施方面存在顯著差異。在拉丁美洲、中東和非洲，藥物供應、精神科醫護人員數量以及醫療服務的連續性也存在區域差異。在所有地區，可靠的藥物供應、處方醫生的培訓以及患者諮詢都是安全用藥的關鍵。

不同經濟和政策群體之間的醫療保健系統發展程度存在差異。

在東協地區，監管體系、專家資源取得和藥品採購的差異影響著政策的實施。金磚國家成員國在醫療衛生體系、疾病負擔和醫療服務取得途徑方面呈現出極為多樣化的情況。歐盟受益於協調一致的監管原則，但在報銷制度和臨床實踐方面仍存在國家差異。七國集團（G7）的醫療衛生體系通常擁有成熟的藥品安全監測系統和專家網路，而海灣合作理事會（GCC）國家則正透過不同的途徑拓展其醫療衛生體系。同樣，北約成員國在處方集和精神健康基礎設施方面也存在差異，儘管集團層面的協調是有益的，但如果沒有國家層面的規劃，則遠遠不夠。

每個國家的具體情況將決定實際執行和監督方式。

在澳洲、加拿大、法國、德國、義大利、日本、韓國、英國、英國和美國，針對複雜抗憂鬱症療法的監管和臨床框架已基本建立，但處方集和處方實踐方面仍存在差異。在巴西、墨西哥、印度、中國、俄羅斯和其他目標市場，患者獲得專科醫生服務、藥物配發、診斷能力和治療連續性方面存在差異。國家層級的優先事項包括：統一的附加檔、考慮藥物交互作用的電子處方、確保訓練有素的臨床醫生隊伍，以及明確的副作用監測和治療過渡流程。

優先考慮安全通道、專業訓練和證據收集。

業界領導者應改善藥物交互作用篩檢工具，提供簡潔的飲食和用藥諮詢，並支持處方醫師、藥師和病患的教育。產品規劃應考慮特定製劑的安全要求、可靠的分銷管道以及清晰的治療過渡指導。雖然與醫療保健系統的合作可以改善藥物安全監測和用藥依從性支持，但真實世界研究應檢驗藥物在不同人群中的療效、耐受性和可及性。所有數位化或人工智慧驅動的解決方案都必須經過臨床檢驗，並納入明確的人工審核。

整合來自臨床、監管和醫療保健系統的證據。

本執行摘要在概念上補充了關於單胺氧化酶抑制劑（MAOIs）的既定臨床和監管考量，並基於對所提供市場範圍的結構化解讀。一項嚴謹深入的研究將涉及交叉引用處方資訊、治療指南、同行評審文獻、藥物安全監測記錄、監管資料庫、處方集文件，以及與臨床醫生和藥劑師的訪談。研究結果應按地區進行交叉引用，按劑型和適應症分類，並評估證據的品質、相關性和適用性。本文未使用任何市場估算、預測或市佔率資料。

單胺氧化酶抑制劑仍是一種需要嚴格管理的特殊治療方法。

儘管面臨嚴格的安全要求和其他療法的競爭，單胺氧化酵素抑制劑（MAOIs）在神經精神疾病治療中仍發揮重要作用。其未來的重要性與其說是取決於廣泛的應用，不如說是取決於合適的患者選擇、可靠的用藥途徑、嚴格的用藥管理以及專業專家的充分監督。鑑於地區和國家差異，靈活且因地制宜的用藥方案至關重要，而檢驗的數位化工具和精心管理的AI則有望提升安全性、監測效果和治療個體化程度。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：單胺氧化酵素抑制劑市場：依適應症分類

  • 重度憂鬱症
    • 非典型憂鬱症
    • 難治性憂鬱症
  • 帕金森氏症
    • 晚期
    • 初期

第8章：單胺氧化酵素抑制劑市場：依分子類型分類

  • 非選擇性MAO抑制劑
    • 異卡波肼
    • 芬那嗪
    • 反式環丙胺
  • 選擇性MAO-B抑制劑
    • Rasagiline
    • 沙芬醯胺
    • Selegiline

第9章：單胺氧化酵素抑制劑市場：依給藥途徑分類

  • 口服
  • 經皮給藥

第10章：單胺氧化酵素抑制劑市場：以劑型分類

  • 膠囊
  • 修補
  • 藥片

第11章：單胺氧化酵素抑制劑市場：依最終用戶分類

  • 醫院
  • 網路藥房
  • 零售藥房
  • 專科診所
    • 神經內科診所
    • 精神病診所

第12章：單胺氧化酵素抑制劑市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：單胺氧化酵素抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：單胺氧化酵素抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • Apotex Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gedeon Richter Plc
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lundbeck A/S
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Servier Laboratories
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第17章 主要專家

Product Code: MRR-9C4233EE7D55

The Monoamine Oxidase Inhibitors Drugs Market is projected to grow by USD 2.57 billion at a CAGR of 7.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.57 billion
Estimated Year [2026] USD 1.65 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 7.31%

Monoamine Oxidase Inhibitors in Contemporary Neuropsychiatric Care

Monoamine oxidase inhibitors (MAOIs) are prescription medicines used primarily in selected depressive disorders and, for certain formulations, Parkinson's disease. They act by reducing the breakdown of monoamine neurotransmitters, including serotonin, norepinephrine, and dopamine. Their clinical use is constrained by food and medicine interactions, adverse-effect risks, and the availability of other therapies, but they remain relevant when treatment response is inadequate or specific clinical needs justify their use.

Safety Management and Treatment Positioning Are Reshaping Use

The landscape is being shaped by stronger emphasis on medication reconciliation, dietary counseling, interaction screening, and specialist supervision. Clinicians must distinguish between irreversible and reversible inhibition, account for washout periods, and manage risks associated with hypertensive reactions or serotonin toxicity. Transdermal and selective formulations may reduce some practical barriers, while individualized treatment selection and closer follow-up are increasing the importance of patient education and coordinated care.

Artificial Intelligence Supports Safer, More Individualized Decisions

Artificial intelligence can contribute to MAOI care by identifying potential drug interactions across complex medication lists, flagging contraindicated combinations, and supporting clinical decision workflows. It may also assist pharmacovigilance by detecting patterns in adverse-event reports and help researchers identify patient characteristics associated with response or intolerance. These applications require validated clinical evidence, transparent reasoning, privacy safeguards, and clinician oversight; AI should support, rather than replace, prescribing judgment.

Regional Differences Reflect Regulation, Access, and Specialist Capacity

In North America and Europe, use is influenced by established prescribing guidance, specialist services, and detailed interaction-management requirements. Asia-Pacific combines advanced neuropsychiatric care in countries such as Australia, Japan, and South Korea with substantial variation in access and clinical infrastructure across the region. Latin America, the Middle East, and Africa face differing levels of medicine availability, psychiatric workforce capacity, and continuity of care. Across all regions, reliable supply, prescriber training, and patient counseling are central to safe utilization.

Economic and Policy Groups Show Uneven Health-System Readiness

Within ASEAN, differences in regulatory systems, specialist availability, and medicine procurement affect implementation. BRICS members span highly varied healthcare capacity, disease burdens, and access pathways. The European Union benefits from coordinated regulatory principles but retains national differences in reimbursement and clinical practice. G7 systems generally have mature pharmacovigilance and specialist networks, while GCC countries are expanding healthcare capacity with varied approaches to access. NATO members likewise differ in national formularies and mental-health infrastructure, making group-level coordination useful but insufficient without country-specific planning.

Country Context Determines Practical Adoption and Monitoring

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have established regulatory and clinical frameworks for managing complex antidepressant therapy, although formularies and prescribing practices differ. Brazil, Mexico, India, China, Russia, and other covered markets show variation in specialist access, procurement, diagnostic capacity, and continuity of treatment. Country-level priorities include consistent labeling, interaction-aware electronic prescribing, availability of trained clinicians, and clear pathways for monitoring adverse effects and treatment transitions.

Prioritize Safe Access, Specialist Training, and Evidence Generation

Industry leaders should strengthen interaction-screening tools, provide concise dietary and medication counseling, and support education for prescribers, pharmacists, and patients. Product planning should account for formulation-specific safety requirements, reliable distribution, and clear transition guidance. Partnerships with health systems can improve pharmacovigilance and adherence support, while real-world studies should examine effectiveness, tolerability, and access across diverse populations. Any digital or AI-enabled solution should undergo clinical validation and integrate explicit human review.

Evidence Synthesis Across Clinical, Regulatory, and Health-System Sources

This executive summary is based on a structured interpretation of the supplied market scope, supplemented conceptually by established clinical and regulatory considerations for MAOIs. A rigorous full study would triangulate prescribing information, treatment guidelines, peer-reviewed literature, pharmacovigilance records, regulatory databases, formulary documents, and interviews with clinicians and pharmacists. Findings should be cross-checked across geographies, separated by formulation and indication, and assessed for evidence quality, recency, and applicability. No market estimates, market shares, or forecasts are used here.

MAOIs Remain Specialized Therapies Requiring Disciplined Stewardship

Monoamine oxidase inhibitors retain a defined role in neuropsychiatric care despite demanding safety requirements and competition from alternative treatments. Their future relevance depends less on broad use than on appropriate patient selection, dependable access, rigorous interaction management, and informed specialist oversight. Regional and country differences make adaptable implementation essential, while validated digital tools and carefully governed AI may improve safety, monitoring, and treatment personalization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Monoamine Oxidase Inhibitors Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Major Depressive Disorder
    • 7.2.1. Atypical Depression
    • 7.2.2. Treatment Resistant Depression
  • 7.3. Parkinson's Disease
    • 7.3.1. Advanced Stage
    • 7.3.2. Early Stage

8. Monoamine Oxidase Inhibitors Drugs Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Non-Selective MAO Inhibitors
    • 8.2.1. Isocarboxazid
    • 8.2.2. Phenelzine
    • 8.2.3. Tranylcypromine
  • 8.3. Selective MAO-B Inhibitors
    • 8.3.1. Rasagiline
    • 8.3.2. Safinamide
    • 8.3.3. Selegiline

9. Monoamine Oxidase Inhibitors Drugs Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Transdermal

10. Monoamine Oxidase Inhibitors Drugs Market, by Formulation

  • 10.1. Introduction
  • 10.2. Capsule
  • 10.3. Patch
  • 10.4. Tablet

11. Monoamine Oxidase Inhibitors Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies
  • 11.5. Specialty Clinics
    • 11.5.1. Neurology Clinics
    • 11.5.2. Psychiatry Clinics

12. Monoamine Oxidase Inhibitors Drugs Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Monoamine Oxidase Inhibitors Drugs Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Monoamine Oxidase Inhibitors Drugs Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. Apotex Inc.
  • 16.3. AstraZeneca Plc
  • 16.4. Bausch Health Companies Inc.
  • 16.5. Bayer AG
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Dr. Reddy's Laboratories Ltd.
  • 16.8. Eli Lilly and Company
  • 16.9. F. Hoffmann-La Roche AG
  • 16.10. Gedeon Richter Plc
  • 16.11. GlaxoSmithKline plc
  • 16.12. Hetero Drugs Limited
  • 16.13. Hikma Pharmaceuticals PLC
  • 16.14. Johnson & Johnson
  • 16.15. Lundbeck A/S
  • 16.16. Lupin Limited
  • 16.17. Novartis AG
  • 16.18. Pfizer Inc.
  • 16.19. Sandoz International GmbH
  • 16.20. Sanofi SA
  • 16.21. Servier Laboratories
  • 16.22. Sun Pharmaceutical Industries Ltd
  • 16.23. Teva Pharmaceutical Industries Ltd.
  • 16.24. Viatris Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Monoamine Oxidase Inhibitors Drugs Market, Years Considered for the Study
  • FIGURE 2. Global Monoamine Oxidase Inhibitors Drugs Market, Research Design
  • FIGURE 3. Global Monoamine Oxidase Inhibitors Drugs Market, Research Framework
  • FIGURE 4. Global Monoamine Oxidase Inhibitors Drugs Market, Data Triangulation
  • FIGURE 5. Global Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2025 vs 2032 (%)
  • FIGURE 11. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 13. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Monoamine Oxidase Inhibitors Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Monoamine Oxidase Inhibitors Drugs Market Segmentation & Coverage
  • TABLE 2. Global Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Major Depressive Disorder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Major Depressive Disorder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Major Depressive Disorder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Atypical Depression Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Atypical Depression Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Atypical Depression Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Treatment Resistant Depression Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Treatment Resistant Depression Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Treatment Resistant Depression Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Advanced Stage Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Advanced Stage Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Advanced Stage Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Early Stage Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Early Stage Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Early Stage Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 23. Global Non-Selective MAO Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Non-Selective MAO Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Non-Selective MAO Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Isocarboxazid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Isocarboxazid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Isocarboxazid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Phenelzine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Phenelzine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Phenelzine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Tranylcypromine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Tranylcypromine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Tranylcypromine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Selective MAO-B Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Selective MAO-B Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Selective MAO-B Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Rasagiline Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Rasagiline Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Rasagiline Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Safinamide Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Safinamide Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Safinamide Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Selegiline Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Selegiline Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Selegiline Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 48. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 55. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Patch Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Patch Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Patch Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 65. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Neurology Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Neurology Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Neurology Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Psychiatry Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Psychiatry Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Psychiatry Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 86. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 95. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 97. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 98. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 99. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 100. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 101. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 102. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 103. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 104. North America Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 105. North America Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 106. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 108. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 109. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 110. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 111. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 112. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 113. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 114. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 115. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 116. Latin America Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 117. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 119. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 120. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 121. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 122. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 123. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 124. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 125. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 126. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 127. Europe Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 128. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 129. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 130. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 131. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 132. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 133. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 134. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 135. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 136. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 137. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 138. Middle East Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 139. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 140. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 141. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 142. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 143. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 144. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 145. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 146. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 147. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 148. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 149. Africa Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 150. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 152. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 153. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 154. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 155. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 156. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 157. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 158. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 159. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 160. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. ASEAN Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 162. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 163. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 165. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 166. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 167. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 168. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 169. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 170. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 171. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. GCC Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 173. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 174. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 175. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 176. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 177. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 178. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 179. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 180. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 181. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 182. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 183. European Union Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 184. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 185. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 186. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 187. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 188. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 189. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 190. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 191. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 192. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 193. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. BRICS Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 195. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 196. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 197. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 198. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 199. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 200. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 201. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 202. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 203. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 204. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 205. G7 Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 206. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 207. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 208. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 209. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 210. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 211. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 212. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 213. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 214. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 215. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 216. NATO Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 217. Global Monoamine Oxidase Inhibitors Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 218. United States Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 219. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 220. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 221. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 222. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 223. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 224. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 225. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 226. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 227. United States Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 228. United States Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 229. Canada Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 230. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 231. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 232. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 233. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 234. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 235. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 236. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 237. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 238. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 239. Canada Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 240. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 241. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 242. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 243. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 244. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 245. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 246. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 247. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 248. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 249. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 250. Mexico Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 251. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 252. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 253. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 254. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 255. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 256. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 257. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 258. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 259. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 260. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 261. Brazil Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 262. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 263. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 264. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 265. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 266. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 267. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 268. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 269. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 270. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 271. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 272. United Kingdom Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 273. Germany Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 274. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 275. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 276. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 277. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 278. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 279. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 280. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 281. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 282. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 283. Germany Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 284. France Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 285. France Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 286. France Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 287. France Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 288. France Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 289. France Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 290. France Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 291. France Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 292. France Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 293. France Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. France Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 295. Russia Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 296. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 297. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 298. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 299. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 300. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 301. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)
  • TABLE 302. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 303. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 304. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 305. Russia Monoamine Oxidase Inhibitors Drugs Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 306. Italy Monoamine Oxidase Inhibitors Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 307. Italy Monoamine Oxidase Inhibitors Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 308. Italy Monoamine Oxidase Inhibitors Drugs Market Size, by Major Depressive Disorder, 2017-2032 (USD Million)
  • TABLE 309. Italy Monoamine Oxidase Inhibitors Drugs Market Size, by Parkinson's Disease, 2017-2032 (USD Million)
  • TABLE 310. Italy Monoamine Oxidase Inhibitors Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 311. Italy Monoamine Oxidase Inhibitors Drugs Market Size, by Non-Selective MAO Inhibitors, 2017-2032 (USD Million)
  • TABLE 312. Italy Monoamine Oxidase Inhibitors Drugs Market Size, by Selective MAO-B Inhibitors, 2017-2032 (USD Million)

TABLE 313